Share-based Compensation (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| HUTCHMED Share Option Scheme |
|
| Share-based Compensation |
|
| Schedule of share option activity and related information |
| | | | | | | | | | | | | Weighted | | Weighted average | | | | | | | average exercise | | remaining | | Aggregate | | | Number of share | | price in US$ per | | contractual life | | intrinsic value | | | options | | share | | (years) | | (in US$’000) | Outstanding at January 1, 2025 | | 29,640,273 | | 4.47 | | 5.99 | | 3,804 | Granted (note) | | 1,493,435 | | 3.27 | | | | | Exercised | | (726,525) | | 2.17 | | | | | Cancelled | | (1,423,610) | | 2.33 | | | | | Expired | | (3,309,340) | | 4.46 | | | | | Outstanding at December 31, 2025 | | 25,674,233 | | 4.59 | | 5.12 | | 1,424 | Exercised | | (7,500) | | 2.50 | | | | | Cancelled | | (1,388,236) | | 3.61 | | | | | Expired | | (1,185,475) | | 5.44 | | | | | Outstanding at June 30, 2026 | | 23,093,022 | | 4.60 | | 4.51 | | 5 | Vested and exercisable at December 31, 2025 | | 20,020,945 | | 4.94 | | 4.23 | | 953 | Vested and exercisable at June 30, 2026 | | 19,802,670 | | 4.79 | | 3.90 | | 5 |
Note: This was granted to an executive director in June 2025 where the number of share options exercisable is subject to certain performance targets based on a market condition covering the 3-year period from 2025 to 2027 which has been reflected in estimating the grant date fair value using the Monte Carlo simulation model. The grant date fair value of such award is US$1.17 per share. Vesting of such award will occur around March 2028 if the performance targets are met.
|
| Schedule of share option exercises |
| | | | | | | Six Months Ended June 30, | | | 2026 | | 2025 | | | | (in US$’000) | Cash received from share options exercised | | 19 | | 1,100 | Total intrinsic value of share options exercised | | 4 | | 526 |
|
| Schedule of share-based compensation expenses |
| | | | | | | Six Months Ended June 30, | | | 2026 | | 2025 | | | | (in US$’000) | Research and development expenses | | 835 | | 1,206 | Selling and administrative expenses | | 106 | | 281 | Cost of revenue | | 30 | | 65 | | | 971 | | 1,552 |
|
| LTIP |
|
| Share-based Compensation |
|
| Schedule of treasury shares (in ordinary share equivalent) held by the Trustee |
| | | | | | | Number of | | Cost | | | treasury shares | | (in US$’000) | As at January 1, 2025 | | 16,717,458 | | 60,924 | Vested | | (4,134,157) | | (15,442) | As at December 31, 2025 | | 12,583,301 | | 45,482 | Vested | | (9,319,020) | | (32,885) | As at June 30, 2026 | | 3,264,281 | | 12,597 |
|
| Schedule of share-based compensation expenses |
| | | | | | | Six Months Ended June 30, | | | 2026 | | 2025 | | | | (in US$’000) | Research and development expenses | | 2,607 | | 5,491 | Selling and administrative expenses | | 1,275 | | 1,811 | Cost of revenue | | 109 | | 389 | | | 3,991 | | 7,691 | Recorded with a corresponding credit to: | | | | | Liability | | 431 | | 630 | Additional paid-in capital | | 3,560 | | 7,061 | | | 3,991 | | 7,691 |
|